{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-26-006848","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2026-09-01T10:00:22+00:00","discovered_at":"2026-09-01T10:10:11.145524+00:00","generated_at":"2026-09-01T10:10:40.478418+00:00","sec_items":["1.01","3.02","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Valion Bio appoints Lisa Wolf President/COO, adds two directors, raises $7.7M from 3i","bullets":["Lisa Wolf becomes President and COO, retains CFO role; former CEO Michael K. Handley has departed.","Jared Malbin (Lucid Capital Markets COO) and Thomas Jensen (Allarity Therapeutics CEO) joined the board.","Letter agreement with 3i: issued 100 Series B and 7,637 Series C preferred plus warrants for $7.737M; $1.5M cash to company.","Warrants cover 1,053,969 shares at $3.62 exercise; $6.137M retained by 3i to satisfy overdue cash true-up.","Lead asset Entolimod targets projected $7.8B Acute Radiation Syndrome market by 2032."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-006848","json":"https://secwatch.observer/filing/0001683168-26-006848.json","markdown":"https://secwatch.observer/filing/0001683168-26-006848.md","text":"https://secwatch.observer/filing/0001683168-26-006848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/0001683168-26-006848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/valion_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-01T10:10:40.478418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}